

Instruction for Use

virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit

The virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit is an assay for the simultaneous detection of the SARS-CoV-2 spike protein mutations E484K and N501Y.

REF

G01136-96



96



gerbion GmbH & Co. KG

Remsstr. 1

70806 Kornwestheim

Germany

phone: +49 7154 806 20 0

fax: +49 7154 806 20 29

e-mail: info@gerbion.com

www.gerbion.com

IVD



Index

| | | |
|-----|---|----|
| 1 | Intended Use | 3 |
| 2 | Principle of the Test | 3 |
| 3 | Package Contents | 3 |
| 4 | Equipment and Reagents to be Supplied by User | 3 |
| 5 | Transport, Storage and Stability..... | 4 |
| 6 | Warnings and Precautions | 4 |
| 7 | Sample Material | 5 |
| 8 | Real time RT-PCR..... | 5 |
| 8.1 | Important Points Before Starting | 5 |
| 8.2 | Procedure | 5 |
| 8.3 | Preparation of the Positive Controls | 5 |
| 8.4 | Instrument Settings | 6 |
| 9 | Data Analysis | 8 |
| 9.1 | Interpretation of the PCR Signals | 8 |
| 9.2 | Interpretation of the melting curve..... | 9 |
| 9.3 | Interpretation of the Results | 11 |
| 10 | Assay Validation | 12 |
| 11 | Limitations of the Method | 12 |
| 12 | Troubleshooting | 12 |
| 13 | Kit Performance | 14 |
| 14 | Abbreviations and Symbols..... | 14 |
| 15 | Literature..... | 14 |

1 Intended Use

The virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit is an assay for the detection of point mutations in the spike protein of SARS-CoV-2 from biological specimens. The test kit is used with samples that have been prequalified with screening PCRs like virellaSARS-CoV-2 seqc real time RT-PCR Kit 2.0 (gerbion, Cat. No. G01128). The determination of a specific lineage requires another test kit, e. g. virellaSARS-CoV-2 mutant (gerbion, Cat. No. G01132).

2 Principle of the Test

The virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit contains specific primer and probe systems for the detection of two SARS-CoV-2 spike protein mutations present in most of the Variants of Concern. The two detected mutations are E484K (present in P.1 (Brazilian Variant) and B.1.351 (South African Variant)) and N501Y which is present in most of the Variants of Concern, including B.1.1.7 (UK Variant), P.1 and B.1.351.

The result of the melting curve does not allow to determine a specific strain or variant of SARS-CoV-2, but it shows the presence of crucial point mutations that are suspected to alter the characteristics of the virus.

3 Package Contents

The reagents supplied are sufficient for 96 reactions.

Table 1: Components of the virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit

| Label | Lid Colour | Content |
|----------------------|------------|-------------|
| Reaction Mix | yellow | 1 x 1325 µl |
| Enzyme | blue | 1 x 19.2 µl |
| Positive Control WT | red | 1 x 50 µl |
| Positive Control Mut | violet | 1 x 50 µl |
| Negative Control | green | 1 x 150 µl |

4 Equipment and Reagents to be Supplied by User

- Sterile microtubes
- Pipets (adjustable volume)
- Sterile pipet tips with filter
- Table centrifuge
- Vortexer
- Real time PCR instrument
- Optical PCR reaction tubes with lid or optical PCR reaction plate with optical foil
- Optional: Liquid handling system for automation
- PCR grade water

5 Transport, Storage and Stability

The virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit is shipped on dry ice or cool packs. All components must be stored at maximum -18°C in the dark immediately after receipt. Do not use reagents after the date of expiry printed on the package. Up to 20 freeze and thaw cycles are possible. For convenience, opened reagents can be stored at +2-8°C for up to 6 months. Protect kit components from direct sunlight during the complete test run.

6 Warnings and Precautions

Read the Instruction for Use carefully before using the product.

Before first use check the product and its components for:

- Use of this product is limited to personnel specially instructed and trained in the techniques of real time PCR procedures.
- Specimens should always be treated as infectious and/or biohazardous in accordance with safe laboratory procedures.
- Avoid microbial and nuclease (DNase/RNase) contamination of the eluates and the components of the kit.
- Always use DNase/RNase-free disposable pipet tips with aerosol barriers.
- Always wear protective disposable powder-free gloves when handling kit components.
- Use separated and segregated working areas for (1) sample preparation, (2) reaction setup and (3) amplification/detection activities. The workflow in the laboratory should proceed in unidirectional manner. Always wear disposable gloves in each area and change them before entering a different area.
- Dedicate supplies and equipment to the separate working areas and do not move them from one area to another.
- Store positive and/or potentially positive material separated from all other components of the kit.
- Do not open the reaction tubes/plates post amplification to avoid contamination with amplicons.
- Additional controls may be tested according to guidelines or requirements of local, state and/or federal regulations or accrediting organizations.
- Do not autoclave reaction tubes after the PCR since this will not degrade the amplified nucleic acid and will bear the risk to contaminate the laboratory area.
- Discard sample and assay waste according to your local safety regulations.

7 Sample Material

Starting material for virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit is RNA qualified SARS-CoV-2 positive by real time RT-PCR (e. g. virellaSARS-CoV-2 seqc real time RT-PCR Kit 2.0, gerbion, Cat. No. G01128).

Eluates with very low copy numbers resulting in C_T values >32 are not suitable for testing with the virellaSARS-CoV-2 mutant 2 real time RT-PCR.

8 Real time RT-PCR

8.1 Important Points Before Starting

- Please pay attention to the chapter 6 ,Warnings and Precautions‘.
- Before setting up the real time RT-PCR familiarise yourself with the real time PCR instrument and read the user manual supplied with the instrument.
- The programming of the thermal profile should take place before the RT-PCR set up.
- In every RT-PCR run one Positive Control WT, one Positive Control Mut and one Negative Control should be included.
- Before each use, all reagents should be thawed completely at room temperature, thoroughly mixed (except the Enzyme) and centrifuged very briefly.
- Due to the high viscosity of the Enzyme (blue lid), prewarming at room temperature for 15 min is recommended.

8.2 Procedure

Prepare the Master Mix according to Table 2.

Prepare a volume of Master Mix for at least one sample more than required, in order to compensate for pipetting inaccuracy.

Table 2: Preparation of the Master Mix

| Volume per Reaction | Volume Master Mix |
|---------------------------|----------------------|
| 13.8 μ l Reaction Mix | 13.8 μ l x (N+1) |
| 0.2 μ l Enzyme | 0.2 μ l x (N+1) |

8.3 Preparation of the Positive Controls

The Positive Control WT and the Positive Control Mut are stored in an extra storage buffer which may alter the peak of the melting curves. For a better comparison with the samples, both Positive Controls need to be freshly diluted 1:10 in PCR grade water before each PCR run.

Prepare the Positive Control according to Table 3.

Table 3: Preparation of the Positive Controls

| Component | Volume |
|----------------------------|------------|
| Positive Control WT or Mut | 2 μ l |
| PCR grade water | 18 μ l |

Real time RT-PCR set-up

- Place the number of optical PCR reaction tubes needed into the respective tray of the real time PCR instrument / take an optical PCR reaction plate.
- Pipet **14 μ l** of the Master Mix into each optical PCR reaction tube / the optical PCR reaction plate.
- Add **6 μ l** of the eluates, the two Positive Controls and the Negative Control to the corresponding optical PCR reaction tube / the optical PCR reaction plate (Table 4).
- Close the optical PCR reaction tubes / the optical PCR reaction plate immediately after filling in order to reduce the risk of contamination.

Table 4: Preparation of the real time RT-PCR

| Component | Volume |
|--------------|--------------|
| Master Mix | 14.0 μ l |
| Sample | 6.0 μ l |
| Total Volume | 20.0 μ l |

8.4 Instrument Settings

For the real time RT-PCR use the thermal profile shown in Table 5.

Table 5: real time RT-PCR thermal profile

| Description | Time | Temperature | Number of Cycles | Acquisition |
|--------------------------------|--|-------------|------------------|-------------|
| <i>Reverse Transcription</i> | 10 min | 45°C | 1 | no |
| <i>Initial Denaturation</i> | 5 min | 95°C | 1 | no |
| <i>Denaturation</i> | 10 sec | 95°C | 45 | no |
| <i>Annealing and Extension</i> | 40 sec | 60°C | | end of step |
| <i>Melting Curve</i> | see the tables below for individual cyler settings | | | |

LightCycler 480II

| Program Step | Melting Curve | | | Cooling |
|-----------------------|----------------|----------|------------|----------|
| Parameter | | | | |
| Analysis Mode | Melting Curves | | | None |
| Cycles | 1 | | | 1 |
| Target [°C] | 95 | 40 | 75 | 40 |
| Hold [hh:mm:ss] | 00:00:30 | 00:02:00 | - | 00:00:30 |
| Ramp Rate [°C/s] | 4.4 | 1.5 | 0.29 | 1.5 |
| Acquisition Mode | None | None | Continuous | None |
| Acquisitions [per °C] | - | - | 1 | - |

Bio-Rad CFX96

| Program Step | Melt Curve |
|--------------|------------------------------|
| Parameter | |
| Melt from | 52.0 °C to 72.0 °C |
| Increment | 0.5 °C for 0:05 + Plate Read |

Mic qPCR Cycler

| Program Step | Melt |
|--------------|--------------------------------|
| Parameter | |
| Melt from | 52.0 °C to 72.0 °C at 0.1 °C/s |
| Acquire on | Green |
| Program Step | Melt |
| Parameter | |
| Melt from | 52.0 °C to 72.0 °C at 0.1 °C/s |
| Acquire on | Red |

NEOS-96 qPCR / NEOS-48 qPCR

| Program Step | Continuous Melt | |
|--------------|-----------------|---------------|
| Parameter | | |
| Cycle | 1 | |
| Step | 1 | 2 |
| Temperature | 52.0 °C | 72.0 °C |
| Time | 00:01 | - |
| Fluorescence | None | 5 Readings/°C |

QuantStudio 5

| Program Step | Melt Curve Stage | |
|--------------|------------------|------------------|
| Parameter | | |
| Step | 1 | 2 (Dissociation) |
| Temperature | 52.0 °C | 72.0 °C |
| Time | 00:01 | 00:01 |
| Ramp Rate | 1.6 °C/s | 0.1 °C/s |

Dependent on the real time PCR instrument used, further instrument settings have to be adjusted according to Table 6.

Table 6: Instrument settings required for the virellaSARS-CoV-2 mutant 2 real time RT-PCR.

| Real time PCR Instrument | Parameter Reaction Mix | Detection Channel | Notes | | |
|--------------------------|------------------------|-------------------|----------------------------------|--------------|----------------------------|
| | | | Colour Compensation not required | | |
| | | | Melt Factor | Quant Factor | Max Integration Time (sec) |
| LightCycler 480II | E484K | 465-510 | 1 | 10 | 1 |
| | N501Y | 618-660 | 1 | 10 | 3 |
| Bio-Rad CFX96 | E484K | FAM | Reference Dye: None | | |
| QuantStudio 5 | N501Y | Cy5 | | | |
| Mic qPCR Cyclcr | E484K | Green | Gain 8 | | |
| | N501Y | Red | Gain 10 | | |
| NEOS-48 qPCR | E484K | FAM | Reference Dye: None | | |
| NEOS-96 qPCR | N501Y | Cy5 | | | |

9 Data Analysis

9.1 Interpretation of the PCR Signals

SARS-CoV-2 positive samples should show amplification curves in the FAM and Cy5 channel. The presence of the curves in the amplification process is no criteria for the data analysis.

SARS-CoV-2 negative sample must show no amplification curve.

9.2 Interpretation of the melting curve

Figure 1 and Figure 2 show examples for real time RT-PCR melting curve results of the mutations and the wildtype (WT) of SARS-CoV-2 spike proteins.




Fig 1: The melting curve of a sample positive for the E484K mutation (red line, peak at 59 °C) in comparison to the melting curve of a wildtype sample (dashed blue line, peak at 63.5 °C).




Fig 2: The melting curve of a sample positive for the N501Y mutation (red line, peak at 61 °C) in comparison to the melting curve of a wildtype sample (dashed blue line, peak at 65 °C).

9.3 Interpretation of the Results

The melting point of the Positive Control WT should be around 4 degrees higher than the melting point of the Positive Control Mut. It must be possible to clearly assign the peaks of the samples to one of the peaks of the Positive Controls. Their melting points may only deviate by ± 1.0 degrees from that of the corresponding Positive Control.

Furthermore, it is essential to look at the melting curves for the associated values given by the cycler. Melting peaks can occur which are not evaluated by the cycler but can be clearly evaluated optically.

Table 7: Interpretation of the results for virellaSARS-CoV-2 mutant 2

| Channel | Melting Peak | Interpretation |
|------------|--|---|
| FAM | Melting peak of the sample aligned with melting peak of Positive Control Mut | E484K mutation is detected |
| | Melting peak of the sample aligned with melting peak of Positive Control WT | Wildtype is detected |
| | Melting peak of the sample not aligned with melting peak of one of the Positive Controls | another mutation is possible |
| | No melting peak | not enough sample material or SARS-CoV-2 negative |
| Cy5 | Melting peak of the sample aligned with melting peak of Positive Control Mut | N501Y mutation is detected |
| | Melting peak of the sample aligned with melting peak of Positive Control WT | Wildtype is detected |
| | Melting peak of the sample not aligned with melting peak of one of the Positive Controls | another mutation is possible |
| | No melting peak | not enough sample material or SARS-CoV-2 negative |

10 Assay Validation

Negative Control

The Negative Control must show no peak in the melting curve in the FAM and Cy5 channel.

Positive Control WT

The Positive Control WT must show a peak in the melting curve in the FAM and Cy5 channel.

Positive Control Mut

The Positive Control Mut must show a peak in the melting curve in the FAM and Cy5 channel which is around 4 degrees lower than the peak of the Positive Control WT.

11 Limitations of the Method

- Strict compliance with the Instruction for Use is required for optimal results.
- Use of this product is limited to personnel specially instructed and trained in the techniques of real time PCR and in vitro diagnostic procedures.
- Good laboratory practice is essential for proper performance of this assay.
- All reagents should be closely monitored for impurity and contamination. Any suspicious reagents should be discarded.
- This assay must not be used on a biological specimen directly. Appropriate nucleic acid extraction methods have to be conducted prior to using this assay.
- As with any diagnostic test, results of the virellaSARS-CoV-2 mutant 2 real time RT-PCR Kit need to be interpreted in consideration of all clinical and laboratory findings.

12 Troubleshooting

The following troubleshooting guide is included to help you with possible problems that may arise when performing a real time RT-PCR. If you have further questions, please do not hesitate to contact our scientists on info@gerbion.com.

No melting curve peaks in the FAM and/or Cy5 channel of the Positive Controls

| | |
|--|--|
| The selected channel for analysis does not comply with the protocol | Select the detection channels according to Table 6. |
| Incorrect preparation of the Master Mix | Make sure that the Enzyme is added to the Master Mix (chapter 8). |
| Incorrect configuration of the real time RT-PCR | Check your work steps and compare with chapter 8. |
| The programming of the thermal profile is incorrect | Compare the thermal profile with the protocol 'Instrument Settings' in Table 5 and Table 6. |
| Incorrect storage conditions for one or more kit components or kit expired | Check the storage conditions and the date of expiry printed on the kit label. If necessary, use a new kit and make sure kit components are stored as described in 'Transport, Storage and Stability' |

No melting curve peaks in the FAM and/or Cy5 channel in a sample

| | |
|--|--|
| The sample does not contain enough RNA to guarantee a proper result. | Review the prequalification of the screening PCR. If the Ct value for SARS-CoV-2 detection is >35, the eluate is not suitable. If the Ct value is <35 repeat the PCR with this sample. |
|--|--|

Detection of a melting curve peak in the FAM and/or Cy5 channel of the Negative Control

| | |
|--|---|
| Contamination during preparation of the real time RT-PCR | Repeat the real time RT-PCR in replicates. If the result is negative in the repetition, the contamination occurred when the samples were pipetted into the optical PCR reaction tubes. Make sure to pipet the Positive Controls last and close the optical PCR reaction tube immediately after adding the sample. If the same result occurs, one or more of the kit components might be contaminated. Make sure that workspace and instruments are decontaminated regularly. Use a new kit and repeat the real time RT-PCR. |
|--|---|

The peaks of the melting curve do not align with the 'Data Analysis'










| | |
|---|---|
| Atypical peaks appear at the beginning or ending of the melting curve | Peaks close to the beginning or the ending of the melting curves should not be considered in the data analysis. |
| The Positive Controls were not diluted for the PCR reaction | Peaks of the Positive Controls are lowered by 2 degrees. |
| Sensitivity, fluorescence intensity and melt peak may differ on individual real time PCR Cyclers. | The samples should be aligned with the two provided Positive Controls. |

13 Kit Performance

The adjustment and validation of the virellaSARS-CoV-2 mutant 2 real time RT-PCR kit is an ongoing process. Hence, comparison data from sequences of eluted SARS-CoV-2 RNA are evaluated continuously.

Detailed information based on the latest state of knowledge is available at gerbion GmbH & Co.KG. Please address your inquiry to info@gerbion.com.

14 Abbreviations and Symbols

| | | | |
|--|---|---|---|
| RNA | Ribonucleic Acid |  | Content sufficient for <n> tests |
| RT-PCR | Reverse Transcription Polymerase Chain Reaction |  | Upper limit of temperature |
| REACTION MIX | Reaction Mix |  | Manufacturer |
| ENZYME | Enzyme |  | Use by YYYY-MM-DD |
| CONTROL WT  | Positive Control WT | LOT | Batch code |
| CONTROL MUT  | Positive Control Mut | CONT | Content |
| CONTROL  | Negative Control |  | Consult instruction for use |
| REF | Catalog number | IVD | <i>In vitro</i> diagnostic medical device |
| | |  | European Conformity |

15 Literature

- [1] www.who.int/health-topics/coronavirus
- [2] Rambaut et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. nCoV-2019 Genomic Epidemiology
- [3] Garry. Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage. nCoV-2019 Genomic Epidemiology
- [4] Faria et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. nCoV-2019 Genomic Epidemiology